Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-05-23
2006-05-23
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C514S002600
Reexamination Certificate
active
07048926
ABSTRACT:
The invention provides methods for using agonists and antagonists of FabK polypeptides, particularly to modulate the metabolism of bacteria or to treat bacterial infection.
REFERENCES:
patent: 3940478 (1976-02-01), Kurtz
patent: 4978332 (1990-12-01), Luck et al.
patent: 5539132 (1996-07-01), Royer et al.
patent: 5614551 (1997-03-01), Dick et al.
patent: 5759837 (1998-06-01), Kuhajda et al.
patent: 5965402 (1999-10-01), Black et al.
patent: 6228619 (2001-05-01), Foster et al.
patent: 6274376 (2001-08-01), Black et al.
patent: 6380370 (2002-04-01), Doucette-Stamm et al.
patent: 6403337 (2002-06-01), Bailey et al.
patent: 6432670 (2002-08-01), Payne et al.
patent: 6593114 (2003-07-01), Kunsch et al.
patent: 6613553 (2003-09-01), Rock et al.
patent: 2002/0076766 (2002-06-01), Black eet al.
patent: 26 20 777 (1977-12-01), None
patent: 0 78 6519 (1997-07-01), None
patent: 0 826 774 (1998-04-01), None
patent: 10-174590 (1998-06-01), None
patent: WO 97/30070 (1997-08-01), None
patent: WO 97/30149 (1997-08-01), None
patent: WO 98/06734 (1998-02-01), None
patent: WO 98/18931 (1998-05-01), None
patent: WO 98/24475 (1998-06-01), None
patent: WO 98/26072 (1998-06-01), None
patent: WO 00/70017 (2000-11-01), None
patent: WO 01/27103 (2001-04-01), None
patent: WO 01/30988 (2001-05-01), None
patent: WO 01/48248 (2001-07-01), None
patent: WO 01/49721 (2001-07-01), None
patent: WO 01/70995 (2001-09-01), None
patent: WO 02/31128 (2002-04-01), None
patent: WO 03/088897 (2003-10-01), None
Bhargava et al., “Triclosan: Applications and Safety,” American Journal of Infection Control, 24:209-218 (1996).
Rock et al., “Preparative Enzymatic Synthesis and Hydrophopic Chromatography of Acyl-Acyl Carrier Protein,” The Journal of Biological Chemistry, 254(16):7123-7128 (1979).
Rock et al., “Lipid Metabolism in Prokaryotes,” Biochemistry of Lipids, Lipoproteins and Membranes, Elsevier Publishing Company Amsterdam, 35-74 (1996).
Rock et al., “Escherichia colias a model for the regulation of dissociable (type II) fatty acid biosynthesis,” Biochimica et Biophysica Acta, 1302:1-16 (1996).
Heath et al., “Mechanism of Triclosan Inhibition of Bacterial Fatty Acid Synthesis,” The Journal of Biological Chemistry, 274(16):11110-11114 (1999).
Gadda et al., “Substrate Specificity of a Nitroalkane-Oxidizing Enzyme,” Archives of Biochemistry and Biophysics, 363(2):309-313 (1999).
McMurray et al., “Triclosan targets lipid synthesis,” Nature, 394:531-532 (1998).
Ross et al., “Molecular Cloning and Analysis of the Gene Encoding the NADH Oxidase fromStreptococcus faecalis10C1,” Journal of Molecular Biology, 227:658-671 (1992).
Bradford, Marion, “A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding,” Analytical Biochemistry, 72:248-254 (1976).
Tchorzewski et al., “Unique primary structure of 2-nitropropane dioxygenase from Hansenula mrakii,” European Journal of Biochemistry, 226:841-846 (1994).
Komuniecki et al., “Electron-transfer flavoprotein from anaerobic Ascaris suum mitrochondria and its role in NADH-dependent 2-methyl branched-chain enoyl-CoA reduction,” Biochimica et Biophysica Acts, 975:127-131 (1989).
Baker et al., “Enoyl-acyl-carrier-proteon reductase andMycobacterium tuberculosisInhA do not conserve the Try-Xaa-Xaa-Xaa-Lys motif in mammalian 11β- and 17β-hydroxysteriod dehydrogenases and Drosophila alcohol dehydrogenase,” Biochemical Journal, 309:1029-1030 (1995).
Gibson et al., “Contribution of NADH Oxidase to Aerobic Metabolism ofStreptococcus pyogenes,” Journal of Bacteriology, 182(2):448-455 (2000).
Boynton et al., “Cloning, Sequencing, and Expression of Clustered Genes Encoding β-Hydroxybutyrl-Coenzyme A (CoA) Dehydrogenase, Crotonase, and Butyrl-CoA Dehydrogenase from Clostridium acetobutylicum ATCC 824,” Journal of Bacteriology, 178(1):3015-3024 (1996).
Heasley et al., “Kinetic Mechanism and Substrate Specificity of Nitroalkane Oxidase,” Biochemical and Biophysical Research Communication, 225:6-10 (1996).
Havarstein et al., “An unmodified heptadecapeptide pheromone induces competence for genetic transformation inStreptococcus pneumoniae,” Proceedings of the National Academy of Science USA, 92:11140-11144 (1995).
Deiz-Gonzalez et al., “NAD-Independent Lactate and Butyryl-CoA Dehydrogenases of Clostridium acetobutylicum P262,” Current Microbiology, 34:162-166 (1997).
Slater-Radosti et al., “Biochemical and genetic characterization of the action of triclosan onStaphylococcus aureus,” Journal of antimicrobial Chemotherapy, 48:1-6 (2001).
Heath et al., “A triclosan-resistant bacterial enzyme,” Nature, 406:145-146 (2000).
Heath et al., “Broad Spectrum Antimicrobial Biocides Target the Fabl Component of Fatty Acid Synthesis,” The Journal of Biological Chemistry, 283(46):30316-30320 (1998).
Saito et al., “Genetic Evidence that Phosphatidylserine Synthaso II Catalyzes the Conversion of Phosphatidylethanolamine to Phosphatidylserine in Chinese Hamster Ovary Cells,” The Journal of Biological Chemistry, 273(27):17199-17205 (1998).
Roujeinikova et al., “Inhibitor Binding Studies on Enoyl Reductase Reveal Conformational Changes Related to Substrate Recognition,” The Journal of Biological Chemistry, 274(43):30811-30817 (1999).
Bergler et al., “Protein EnvM is the NADH-dependent Enoyl-ACP Reductase (Fabl) ofEscherichia coli,” The Journal of Biological Chemistry, 269(8):5493-5496 (1994).
Duran et al., “Characterization of cDNA Clones for the 2-Methyl Branched-chain Enoyl-CoA Reductase,” The Journal of biological Chemistry, 268(30):22391-22396 (1993).
Volkman et al., “Biosynthesis of D-Alanyl-Lipoteichoic Acid: The Tertiary Structure of apo-D-Alanyl Carrier Protein,” Biochemistry, 40:7964-7972 (2001).
Ward et al., “Kinetic and Structural Characteristics of the Inhibition of Enoyl (Acyl Carrier Protein) Reductase by Triclosan,” Biochemistry, 38:12514-12525 (1999).
Parkh et al., “Roles of Tyrosine 168 and Lysine 165 in the Catalytic mechanism of InhA, the Enoyl-ACP Reductase fromMycobacterium tuberculosis,” Biochemistry, 38:13623-13634 (1999).
Roujeinikova et al., “Crystallographic Analysis of Triclosan Bound to Enoyl Reductase,” Journal of Molecular Biology, 294:527-535 (1999).
Heath et al., “Inhibition of theStaphylococcus aureusNADPH-dependent Enoyl-Acyl Carrier Protein Reductase by Triclosan and Hexachlorophene,” The Journal of Biological Chemistry, 275(7):4654-4659 (2000).
Heath et al., “Inhibition of β-Ketoacyl-Acyl Carrier Protein Synthase III (FabH) by Acyl-Acyl Carrier Protein inEscherichia coli,” The Journal of Biological Chemistry, 271(18):10996-11000 (1996).
Heath et al., “Roles of the FabA and FabZ β-Hydroxyacyl-Acyl Carrier Protein Dehydrateses inEscherichia coliFatty Acid Biosynthesis,” The Journal of Biological Chemistry, 271(44):27795-27801 (1996).
Heath et al., “The Enoyl-[acyl-carrier-protein] Reductases Fabl and FabL fromBacillus subtilis,” The Journal of Biological Chemistry, 275(51):40128-40133 (2000).
Heath et al., “Regulation of Fatty Acid Elongation and Initiation by Acyl-Acyl Carrier Protein inEscherichia coli,” The Journal of Biological Chemistry, 271(4):1833-1836 (1996).
Bunzow et al., “Cloning and expression of a rat D2dopamine receptor cDNA,” Nature, 336:783-787 (1988).
Whitfield et al., “Purification and Properties of Electron-transferring Flavoprotein andPeptostreptococcus eisdenii,” The Journal of Biological Chemistry, 249(9):2801-2810 (1974).
Baldwin et al., “Electron transport inPeptostreptococcus elsdenii,” Biochimica et Biophysica Acts, 92:421-432 (1964).
Heath et al., “Enoyl-Acyl Ca
Brandt Martin
DeWolf, Jr. Walter E.
Keller Paul M.
Patel Arunbhai H.
Payne David J.
Affinium Pharmaceuticals, Inc.
Foley & Hoag LLP
Navarro Mark
LandOfFree
Methods of agonizing and antagonizing FabK does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of agonizing and antagonizing FabK, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of agonizing and antagonizing FabK will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3574661